拜耳和Cradle达成合作，以加强人工智能驱动的抗体发现与优化-动脉网

Bayer and Cradle enter collaboration to enhance AI-enabled antibody discovery and optimization

拜耳等信源发布 2026-01-07 20:09



可切换为仅中文







January

一月

2026

13:00 PM

下午1:00

Europe/Amsterdam

欧洲/阿姆斯特丹

Bayer and Cradle enter collaboration to enhance AI-enabled antibody discovery and optimization

拜耳和Cradle达成合作，以加强人工智能驱动的抗体发现与优化

Not intended for UK Media

不适用于英国媒体

Summary

摘要

Cradle provides a scientific AI software platform focused on protein engineering / Bayer continues to utilize AI in R&D, reinforcing commitment to modernize and scale its drug discovery and development efforts / Bayer and Cradle to jointly work on a machine learning research project to further develop capabilities.

Cradle提供了一个专注于蛋白质工程的科学AI软件平台/Bayer继续在研发中利用AI，强化其现代化和扩大药物发现与开发工作的承诺/Bayer和Cradle将共同开展一个机器学习研究项目，以进一步提升能力。

Berlin, Amsterdam and Zurich, January 7, 2026

柏林、阿姆斯特丹和苏黎世，2026年1月7日

– Bayer and Cradle today announced that they have entered a three-year strategic collaboration to deploy Cradle’s scientific AI software platform for protein engineering. As part of the collaboration, Bayer will integrate the generative AI platform into existing R&D workflows to enhance lead generation and optimization across its therapeutic antibody pipeline..

– 拜耳和Cradle今天宣布，他们已达成一项为期三年的战略合作，将部署Cradle的科学人工智能软件平台用于蛋白质工程。作为合作的一部分，拜耳会将该生成式人工智能平台整合到现有的研发工作流程中，以增强其治疗性抗体管线的先导物生成与优化。

Bayer selected Cradle's platform to bring higher-quality molecules into clinical development faster by reducing the number of optimization cycles, improving molecular potency, safety and manufacturability, and increasing probability of technical success as Bayer expands to more demanding modes of action..

拜耳选择Cradle的平台，通过减少优化周期数量、提高分子效力、安全性及可制造性，并在拓展至更具挑战性的作用模式时提升技术成功概率，从而更快地将更高质量的分子引入临床开发。

“We believe AI-driven molecule design, discovery and optimization will be a key accelerator of our productivity moving forward,” said Anastasia Hager, Ph.D., Global Head of Drug Discovery Sciences at Bayer’s Pharmaceuticals Division. “Cradle’s platform provides us with scalable scientist-centric solutions to maximize the opportunities in our biologics portfolio and potentially deliver faster, more effective medicines to patients.”.

“我们相信，人工智能驱动的分子设计、发现和优化将成为我们未来生产力提升的关键加速器，”拜耳制药部门全球药物发现科学主管Anastasia Hager博士表示。“Cradle的平台为我们提供了以科学家为中心的可扩展解决方案，以最大化我们在生物制品组合中的机会，并有可能更快地为患者提供更有效的药物。”

“Bayer’s decision reflects a broader shift we’re seeing: leading drug discovery organizations want AI that scales across portfolios, formats, and teams without requiring every scientist to become an ML expert or limiting AI's impact to asset-based deals,” said Stef van Grieken, Co-founder and CEO of Cradle.

“拜耳的决定反映了一个我们正在看到的更广泛的趋势：领先的药物发现组织希望人工智能能够跨投资组合、格式和团队扩展，而不需要每位科学家都成为机器学习专家，也不希望人工智能的影响仅限于基于资产的交易，”Cradle联合创始人兼首席执行官斯特凡·范·格里肯表示。

“Cradle brings enterprise-grade, lab-in-the-loop AI into the hands of the expert scientists working daily to design new molecules and treat diseases, helping reduce iterations while improving potency, developability, and manufacturability. We’re excited to work with Bayer to operationalize AI at scale and translate it into faster, higher-quality candidates for the clinic.”.

“Cradle 将企业级、实验室闭环的人工智能交到每天致力于设计新分子和治疗疾病的专家科学家手中，帮助减少迭代次数，同时提高效力、可开发性和可制造性。我们很高兴与拜耳合作，在大规模上实施人工智能，并将其转化为更快、更高质量的临床候选药物。”

Under the agreement, Cradle will provide Bayer’s antibody scientists with full access to its scientific AI software platform supporting a lab-in-the-loop approach, streamlined design-test-learn cycles, and coordinated execution across laboratory and external partners. Following a successful proof of concept, Bayer selected Cradle as its best suited partner from among several vendors..

根据协议，Cradle 将为拜耳的抗体科学家提供其科学人工智能软件平台的完全访问权限，该平台支持实验室闭环方法、简化设计-测试-学习周期，并协调实验室和外部合作伙伴的执行。在一次成功的概念验证之后，拜耳从数家供应商中选择了 Cradle 作为最适合的合作伙伴。

The collaboration builds on the internal strengths of Bayer in antibody design, synthesis and machine learning, complementing with Cradle’s deep expertise in scalable software development. Bayer and Cradle will also jointly work on a machine learning research project aimed at extending these capabilities even further..

这项合作建立在拜耳在抗体设计、合成和机器学习方面的内部优势之上，并结合了Cradle在可扩展软件开发方面的深厚专业知识。拜耳和Cradle还将共同开展一个机器学习研究项目，旨在进一步扩展这些能力。

About Cradle

关于Cradle

Cradle’s mission is to make engineering biology easier, quicker and more cost-effective. Its enterprise-grade AI software platform currently serves 6 out of the top 25 global pharma companies, and is used across over 50 R&D programs. With Cradle, scientists can engineer better proteins, faster and more successfully, speeding up the development cycle of new therapeutics and bio-based products such as, antibodies, enzymes, and bio-based materials by up to 12x.

Cradle的使命是让工程生物学更容易、更快速、更具成本效益。其企业级AI软件平台目前服务于全球前25大制药公司中的6家，并应用于50多个研发项目。通过Cradle，科学家能够更快、更成功地设计出更优质的蛋白质，将抗体、酶和生物基材料等新型治疗药物和生物产品的开发周期加快多达12倍。

Cradle is based in Amsterdam, The Netherlands; Zurich, Switzerland and the United States with a team of machine learning and biotech research specialists with experience at many of the world’s leading technology and biotech companies, including Google, Novartis, Meta, Zymergen, Uber, Deepmind and Generate Biomedicines.

Cradle 总部位于荷兰阿姆斯特丹、瑞士苏黎世和美国，团队由机器学习和生物技术研究专家组成，这些专家曾在许多世界领先的科技和生物技术公司工作，包括谷歌、诺华、Meta、Zymergen、优步、DeepMind 和 Generate Biomedicines。

Cradle is backed by IVP as well as Index Ventures and Kindred Capital. For more information, visit .

Cradle 得到了 IVP、Index Ventures 和 Kindred Capital 的支持。欲了解更多信息，请访问。

cradle.bio

摇篮生物

。

About Bayer

关于拜耳

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population.

拜耳是一家在全球范围内拥有医疗保健和营养等生命科学领域核心竞争力的企业。秉承“人人健康，无人饥饿”的使命，公司通过支持应对不断增长和老龄化的全球人口所带来的重大挑战，设计其产品和服务以帮助人类和地球繁荣发展。

Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros.

拜耳致力于通过其业务推动可持续发展并产生积极影响。同时，集团旨在通过创新和增长提高盈利能力并创造价值。拜耳品牌在全球范围内代表信任、可靠性和质量。在2024财年，该集团拥有约93,000名员工，销售额达466亿欧元。

R&D expenses amounted to 6.2 billion euros. For more information, go to .

研发费用共计62亿欧元。欲了解更多信息，请访问。

www.bayer.com

。

Find more information at

更多信息请访问

https://pharma.bayer.com

在Facebook上关注我们：

http://www.facebook.com/bayer

Forward-Looking Statements

前瞻性声明

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here.

本发布可能包含基于拜耳管理层当前假设和预测的前瞻性声明。各种已知和未知的风险、不确定性和其他因素可能导致公司的实际未来结果、财务状况、发展或业绩与这里提供的估计存在重大差异。

These factors include those discussed in Bayer’s public reports which are available on the Bayer website at .

这些因素包括拜耳公开报告中讨论的因素，该报告可在拜耳网站上查阅。

www.bayer.com

. The company assumes no liability whatsoever to update these forward-looking statements or to conform

公司不承担更新这些前瞻性声明或使其符合的任何责任 whatsoever

them to future events or developments.

将它们应用于未来的事件或发展。

Bayer Global Media Contact:

拜耳全球媒体联系人：

Derin Denham, phone +1 973 610 7324

德琳·丹哈姆，电话 +1 973 610 7324